Long-term treatment with interferon alfa for myeloproliferative neoplasms
Mené sur des patients atteints d'une thrombocytémie essentielle ou d'une polycythémie vraie, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse, et la toxicité sur le long terme de l'interféron pégylé alpha-2a (durée médiane de suivi : 83 mois)
Interferon alfa has been successfully used for more than 30 years to treat patients with myeloproliferative neoplasms, particularly those with polycythaemia vera or essential thrombocythaemia.1 However, besides this long use and being the topic of hundreds of publications, there is not a clear and consensual appraisal of interferon alfa in myeloproliferative neoplasm management. Respected experts still support the use of chemotherapy, namely hydroxyurea, as the gold standard for first-line therapy of all patients with high-risk polycythaemia vera and essential thrombocythaemia.